<qa>  What is defined as a Grade 3 drug-related adverse event occurring within 28 days after previousA DLT is defined as a Grade 3 drug-related adverse event occurring within 28 days after previous dose excluding tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event using National Cancer Institute NCI Common Terminology Criteria for Adverse Events CTCAE version 4.0 in a single dose cohort. 